Bloodline Research and Supplements Group

Home  /  Evidence ledger  /  NAD+

NAD+

Not a peptide · dinucleotide coenzyme

Not approved

Not a peptide, a coenzyme, and one present in every cell you have. The biology is genuinely important. The case for injecting it is considerably weaker than the marketing suggests, and the oral precursors sit in a different regulatory position again.

Free, no obligation

Ask us anything

Every inquiry gets a real answer from a person. If what you're asking about isn't supported by evidence, we'll say so.

PPNICOTINAMIDEADENINE
Type
Dinucleotide, not a peptide
Formula
C21H27N7O14P2
Mass
663.43 g/mol
Class
Coenzyme

Schematic structure, not to scale. Beads represent amino acid residues along the backbone.

The theory behind it

In theory, raising NAD+ is designed to restore cellular energy metabolism and the sirtuin and PARP enzymes that govern DNA repair and stress response, machinery that measurably declines with age. The underlying biology is first-rate and not in dispute, and oral precursors demonstrably raise NAD+ levels in humans. What remains open is whether raising the level produces the outcomes attached to it.

The detail, if you want it

What it is

Nicotinamide adenine dinucleotide is a coenzyme central to cellular redox reactions and to the function of sirtuins and PARP enzymes. It is not a peptide, despite appearing in peptide catalogues. Levels do decline with age, and that decline is a legitimate and active area of research.

The injectable and IV forms

Not FDA approved. Compounded intravenous NAD+ has drawn regulatory attention, and there is essentially no controlled trial evidence supporting the energy, cognition, or longevity claims made for IV administration. The molecule is also large and unstable, which raises real questions about how much intact NAD+ actually reaches cells versus being broken down and salvaged.

The oral precursors

Nicotinamide riboside and nicotinamide mononucleotide are a separate question. Supplementation with precursors does measurably raise NAD+ levels in humans. That part is established. Whether raising those levels produces clinical benefit is much less clear, and outcome data remains thin. NMN specifically has its own regulatory history: FDA has taken the position that it is excluded from the dietary supplement definition because it was previously investigated as a drug.

What is reasonably established

That NAD+ is essential, that it declines with age, and that precursors raise it. What is not established is that raising it reverses ageing, restores energy, or delivers the outcomes commonly advertised. Those are extrapolations from mechanism, not trial results.

Not sure whether this applies to you?

That is the question a consultation answers. A licensed physician reviews your situation and tells you what the evidence supports. Including when the honest answer is no.

See consultations

Also on the ledger